Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Hosted on MSN11d
New antibody reduces tumor growth in tough-to-treat breast and ovarian cancers: StudyHER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...
MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...
An antibody discovery platform revealed more than 60 monoclonal antibodies specific to patients with alpha-gal syndrome, ...
Recent study conducted by Caushi et al. aimed to evaluate the role of Elisa IgG serum antibody titres in diagnosing pulmonary ...
The following is a summary of “Kinetics of tick-borne encephalitis virus IgM antibody responses in serum and cerebrospinal ...
A study has established the importance of immunoglobulin A, an antibody that is part of the immune system, in generating a response to pneumonia vaccines. Researchers have found that the absence of ...
Researchers at King's College London have developed IgE antibodies targeting HER2-expressing cancers. Early studies show ...
Identifying antibodies for 75% of norovirus outbreaks, University researchers took a step forward in creating a vaccine for ...
Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback